Here are some of the major updates that could move the markets tomorrow:
M&M to invest ₹10,000 crore to set up EV manufacturing plant in Pune
Mahindra & Mahindra (M&M) will invest ₹10,000 crore to set up an electric vehicle (EV) manufacturing plant in Pune, Maharashtra. The automaker has received approval to make the investment from Maharashtra Government’s industrial promotion scheme for EVs. The investment will be made over 7-8 years for setting up the manufacturing facility, development, and production of Mahindra’s upcoming Born Electric Vehicles (BEVs).
Read more here.
HDFC Bank acquires 7.75% stake in Mintoak for ₹31.1 crore
HDFC Bank has acquired a minority stake (7.75%) in Mintoak Innovations Pvt. Ltd for ₹31.1 crore. Mintoak is a fintech start-up that provides a payments-led platform. It offers value-added services to merchants to engage with their customers and for acquirers to enhance their engagement with merchants. The deal is expected to be completed by January 31, 2023.
Read more here.
Bank of Baroda proposes to sell its majority stake in Nainital Bank
Bank of Baroda (BoB) plans to sell its majority stake in Nainital Bank. The bank’s board of directors has approved the divestment of its majority shareholding in Nainital Bank Ltd (NBL) and authorised the issuance of an advertisement inviting Expressions of Interest (EOI) through a Preliminary Information Memorandum (PIM) from interested parties. BoB currently holds a 98.57% equity share capital of NBL.
Read more here.
NTPC crosses 1 GW annual capacity mark in renewable energy segment in FY23
NTPC Ltd has crossed 1 gigawatt (GW) annual capacity in the renewable energy (RE) segment by adding 1,075 megawatts (MW) of renewable energy capacity in the current financial year (FY23). The company’s total non-fossil capacity has reached 9.41%. With this, NTPC’s standalone installed and commercial capacity has become 58,041.27 MW. The group installed and commercial capacity of NTPC has become 70,656.27 MW.
Read more here.
IL&FS resolves debt of ₹56,943 crore; reduces number of entities to 101
IL&FS has resolved its debt of up to ₹56,943 crore by September 30, 2022, through monetization of various assets and reduced the number of entities to 101 from 302. The company, which defaulted on its loan repayment for the first time in September 2018, had to pay back its lenders over ₹90,000 crore at that time. The new board of IL&FS has initiated various measures to reduce debts, which included asset monetisation, debt restructuring, cost optimisation, and liquidity management.
Read more here.
IRCTC’s revenue ‘reduced drastically’ in 2020-21 due to Covid-related restrictions: Govt
IRCTC’s revenue “reduced drastically” by almost 64% during 2020-21, compared to 2019-20 due to Covid-related travel restrictions, said Railway Minister Ashwini Vaishnaw. He added that the revenue increased gradually after the situation normalised. IRCTC earned ₹2,342.41 crore, which went down to ₹861.64 crore during the Covid-affected 2020-21. In 2021-22, the company earned ₹1,952.30 crore.
Read more here.
Torrent Pharma partners with Boehringer Ingelheim to co-market diabetes meds
Torrent Pharmaceuticals Ltd has entered into an alliance with Boehringer Ingelheim to co-market medicines used to treat diabetes and cardiovascular diseases. Both companies entered into a partnership for the sales and co-marketing of Empagliflozin and its combinations. This partnership aims to address the dual challenges of type-2 diabetes and heart failure in India.
Read more here.
NTPC to sell stake in green energy business: Report
According to reports, NTPC Ltd aims to sell a 20% stake in its green energy business this fiscal year, expecting to raise up to ₹3000 crores ($363.97 million). The deal marks the first green transaction by an Indian state company. It has drawn interest from investors, such as Canada Pension Plan Investment Board (CPPIB), Malaysia’s Petronas, and Brookfield.
Read more here.
JB Pharma acquires rosuvastatin brand from Glenmark for ₹314 crore
JB Pharma has acquired cardiac brand Razel (rosuvastatin) from Glenmark Pharma for the India and Nepal region for ₹314 crores. The acquisition will be funded through long-term debt and internal accruals. Razel ranks among the top 10 brands in India in the rosuvastatin molecule category, with combined sales of ₹66.1 crore as of the year-ended October 2022 as per IQVIA data.
Read more here.